Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial.

Trial Profile

Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2011

At a glance

  • Drugs Linezolid (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 09 May 2011 Actual end date changed from Feb 2006 to Jan 2006 as reported by ClinicalTrials.gov.
    • 30 Aug 2006 Status change
    • 10 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top